Author: ryanrutz

The new partnership integrates the BioIntelliSense medical-grade BioButton® wearable and BioDashboard™ clinical intelligence solution with Hicuity Health’s robust patient monitoring services to scale virtual care programs from in-hospital to home.

BioIntelliSense, a leader in continuous health monitoring and clinical intelligence, and Hicuity Health, a leading provider of tech-enabled virtual care services, today announced a strategic partnership to offer fully managed, end-to-end continuous patient monitoring to hospitals and health systems. This partnership addresses critical infrastructure and staffing challenges faced by hospitals and health systems, empowering them to deploy proven, scalable monitoring solutions for in-hospital care, hospital-at-home programs, post-hospital discharge and chronic remote care management.

Through this partnership, the BioIntelliSense FDA-cleared BioButton® multi-parameter device and BioDashboard™ clinical intelligence system will integrate seamlessly with Hicuity Health’s 24/7 virtual patient monitoring services, to provide nurses and other clinicians with actionable health insights and workflow efficiencies. Hicuity Health services are designed to reduce the workforce burden of on-site clinical teams and leverages decades of experience and leadership in high-acuity patient monitoring, delivering over 11 million hours annually of patient monitoring across its nationwide client base.

“The BioIntelliSense award-winning medical-grade solution, combined with Hicuity Health’s extensive experience in patient monitoring services, ensures that health systems of all sizes can now deploy and scale continuous care programs from in-hospital to home,” said James Mault, MD, CEO and Founder of BioIntelliSense. “This partnership addresses current staffing challenges for health systems by offering a comprehensive tech-enabled solution for scalable continuous care that is proven to enable earlier interventions, better patient outcomes, and more efficient use of clinical resources.”

The addition of the Hicuity Health patient monitoring service is an ideal option for hospitals and health systems looking to either initiate or expand their virtual care programs. The rechargeable, wireless BioButton® wearable continuously and passively monitors patient vital signs and biometrics, automating the collection of 1,440 measurements per patient per day. The BioDashboard clinical intelligence engine provides algorithmic-based analytics and vital sign trends which are then securely monitored by Hicuity Health. Hicuity Health’s clinical teams follow predefined workflows and escalation protocols in collaboration with the health system to support timely interventions and better patient outcomes.

“At Hicuity Health, we are committed to transforming the way healthcare is delivered through trusted and innovative virtual care solutions that scale to the needs of hospital systems nationwide,” said Lou Silverman, CEO of Hicuity Health. “By partnering with BioIntelliSense, we’re bringing an unparalleled level of support, flexibility and scalability to hospitals and health systems, helping them provide the highest level of care for patients in-hospital and at-home.” Follow BioIntelliSense on LinkedIn for the latest news and information.

The large-scale study of nearly 12,000 hospitalized patients highlights continuous multiparameter vital sign monitoring resulted in significant positive impact on patient outcomes

BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced publication of peer-reviewed research in the Journal of Clinical Medicine titled, “A Retrospective Observational Study of Continuous Wireless Vital Sign Monitoring via a Medical Grade Wearable Device on Hospitalized Floor Patients.”

This study, which was conducted over 15 months in the medical-surgical units of two U.S. hospitals, highlights the transformative potential of medical-grade wearable monitoring technology and algorithmic-based analytics to enhance patient care. The results demonstrated a reduction in patient length of stay, low alert notification rates reducing alert fatigue, and early clinical intervention when patients experienced deterioration events.

The study utilized the BioIntelliSense BioButton, a multi-parameter continuous monitoring device, placed on a patient’s upper left chest upon hospital admission. The BioButton continuously measured core vital signs including heart rate at rest, respiratory rate at rest, skin temperature, and activity levels, collecting up to 1,440 measurements per patient per day. A total of more than 651,000 patient-hours of vital sign readings were captured over the 15month period, far exceeding what is possible with today’s manual and episodic spot-check collection methods.

The continuous data was wirelessly and securely transmitted via a BioHub™ Wi-Fi® enabled gateway to the BioIntelliSense BioCloud™ for analysis which employed algorithmic and rules-based notifications to alert healthcare providers to adverse vital sign trends and early indications of potential patient deterioration, on average 14.8 hours prior to the patient presenting symptomatic changes.

“The study underscores the value of implementing continuous monitoring wearable technology, combined with algorithmic-based data analytics, in general care areas of the hospital to automate vital sign collection and to deliver clinical intelligence for actionable decision making,” said James Mault, MD, CEO and Founder of BioIntelliSense. “The BioButton system’s ability to deliver timely and accurate notifications enables earlier detection of clinical deterioration and plays a critical role in proactively managing a patient’s health outcomes.”

Key findings from the study include:

• Reduction in hospital stays: length of stay (LOS) in the first unit monitored by the system showed a decreasing trend from 3.07 days to 2.75 days over 12 months which delivers an economic benefit for hospitals and improved satisfaction for patients.
• Early detection of clinical deterioration: among incidences of clinical deterioration, 73% (Site 1) and 66% (Site 2) had at least one vital sign notification within 24 hours prior to the event. On average, the first vital sign notification was triggered 14.8 hours prior to a deterioration event which may allow for earlier, proactive clinical interventions.
• Reduction in alert fatigue: notification rates were <1 per patient per day (0.97 and 0.65 per patient per day at Site 1 and Site 2, respectively), reducing alert noise and fatigue for bedside staff. 40% of patients did not trigger any notifications for their entire stay.
• Accurate vital sign measurements: with the BioButton when compared to manually charted bedside readings in an inpatient setting. Heart rate measurements were highly correlated with a mean difference (clinical bias) of 2 beats per minute. Several patient cases were cited in the study that demonstrate that manually collected respiratory rate is error prone when compared to the accurate and objective continuous measurements captured with the BioButton device. High respiratory rate notifications showed the highest sensitivity for deterioration events.
• Increase in positive patient outcomes: 114 cases saw new or changed physician’s orders as a result of BioButton notifications. Among the new diagnoses were atrial fibrillation, sepsis, and a medication allergy.

All the patients in medical-surgical units enrolled in the study (Site 1 with 119 beds and Site 2 with up to 250 beds) were monitored from a centralized location by a single nurse during weekdays on the day shift. 11,977 patients were monitored as part of the 15-month study.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should” and the negative of these terms or other comparable terminology often identify forward-looking statements. These forward-looking statements, including statements regarding the use of proceeds, are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Ardent Health’s Registration Statement. Except as required by law, Ardent Health has no obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

BioIntelliSense, a continuous health monitoring and clinical intelligence company, announces FDA clearance of the rechargeable BioButton® Multi-Patient wearable and BioDashboard™ system to cost-effectively grow and scale hospital virtual care programs. The BioButton Multi-Patient medical device expands the BioIntelliSense award-winning portfolio of continuous patient monitoring solutions by offering a rechargeable and reusable inpatient solution for automating vital sign collection across medical surgical units, specialty care areas, emergency departments and in delivering hospital level care at home.

The BioDashboard clinical intelligence system’s data-driven exception management enables scalable, automated trending notifications that are personalized for each patient. This facilitates the ability for one clinician to monitor hundreds of BioButton patients simultaneously in a configurable dashboard view for proactive clinical decisions. The transformational shift from episodic to high-frequency continuous vital sign trend monitoring with the FDA-cleared BioButton Multi-Patient wearable and BioDashboard system empowers clinicians to detect clinically meaningful changes in physiologic trends that create opportunities for earlier intervention and improved patient outcomes.

“We are advancing a new standard of care by automating the capture of thousands of multiparameter measurements each day and for every general care patient throughout their inpatient stay and now the BioButton Multi-Patient wearable is conveniently rechargeable with its own dedicated in-facility charging station,” said James Mault, MD, founder and CEO of BioIntelliSense. “The introduction of the rechargeable and reusable BioButton MultiPatient wearable, combined with the BioDashboard clinical intelligence solution, provides health systems nationwide unprecedented economies of scale in making continuous care more affordable and accessible for every patient that is admitted to the hospital.”

The comprehensive BioIntelliSense inpatient monitoring solution – powered by the new BioButton® Multi-Patient wearables and charging stations, BioHub™ Wi-Fi® gateways, BioCloud™ data analytics and the BioDashboard™ clinical intelligence system – provides a scalable continuous care model for improved patient safety and clinical workflow efficiencies by reducing the burden of repetitive manual tasks associated with spot check vital sign measurements and documentation. This staff time savings results in better prioritization of care and re-allocation of resources to those patients who need more hands-on care. Workforce efficiency is further enhanced with the BioDashboard’s exception management approach to continuous patient monitoring with low notification rates (<1 per patient per day) and high clinician engagement (99.71%) through actionable clinical insights that increase response time, reduce alert fatigue and improve overall patient care.

The BioIntelliSense BioButton and BioDashboard System is a sophisticated cloud-based platform that extends from in-hospital to home and is an interoperable solution with robust third party and EMR system integration and data exchange capabilities. BioIntelliSense adheres to strict privacy and security standards and operates with an ecosystem approach that provides our customers the flexibility and scalability that is required to grow their continuous virtual care programs.

The BioIntelliSense FDA-cleared BioButton® multiparameter wearable is now monitoring tens of thousands of patients across more than 2,600 non-ICU beds across Houston Methodist as part of the leading healthcare system’s “Vitals Redesign” initiative to automate continuous vital sign collection, improve patient safety and enhance workflow efficiencies.

BioIntelliSense, a continuous health monitoring and clinical intelligence company, announces completion of Houston Methodist’s inpatient expansion of the BioButton® continuous patient monitoring solution across all 2,653 non-ICU beds at the system’s eight hospitals. The FDA-cleared BioIntelliSense BioButton multi-parameter wearable is applied to patients at the time of admission with centralized command center monitoring by Houston Methodist’s multi-disciplinary team. Applying AI-driven analytics to detect clinically meaningful changes in vital sign trends allow the monitoring team to proactively coordinate care with bedside staff in medical surgical units and within specialty care areas including oncology, cardiology, neurology, transplantation and maternal health.

“Houston Methodist is a recognized leader in innovation and is rapidly transforming care delivery by automating vital sign collection and empowering clinicians to focus on what matters most – their patients,” said James Mault, M.D., founder and CEO of BioIntelliSense. “This system-wide expansion of the BioButton continuous patient monitoring solution demonstrates the clinical value and economic impact of scalable exception management to help identify patients whose condition may be deteriorating as well as those with highly stable vital signs who may be candidates for earlier hospital discharge, thereby reducing length of stay. Together with Houston Methodist, we have scaled a new standard of continuous care with a shared commitment for improving patient outcomes and safety.”

The inpatient monitoring program – powered by the BioButton multiparameter wearable, BioCloud™ data analytics and the BioDashboard™ clinical intelligence solution – reached full scale utilization in an accelerated six-month implementation cycle. The “Vitals Redesign” initiative improves patient safety via continuous monitoring while reducing the burden of repetitive manual tasks associated with spot check vital sign measurements and documentation, enabling caregivers to spend more time focusing on efforts to mobilize patients and other activities that can further improve outcomes. Furthermore, continuous monitoring via the BioButton system is also allowing patients to enjoy better sleep without being woken throughout the night for vital sign measurements.

Today, with the coin-sized wireless BioButton device, up to 1,440 sets of minute-level vital sign measurements are passively captured each day and for every general care patient throughout their inpatient stay. Houston Methodist’s state-of-the-art virtual command center operation monitors high frequency BioButton vital sign data and personalized trend notifications as leading indicators of potential patient deterioration. This exception-based approach to continuous patient monitoring results in low notification rates (<1 per patient per day) and high clinician engagement (99.71%) in performing clinical assessments for more efficient and proactive care.

“Houston Methodist has rapidly advanced from a traditional episodic model of care to a new standard that is more continuous, personalized and proactive,” said Sarah Pletcher, M.D., System Vice President and Executive Medical Director of Strategic Innovation at Houston Methodist. “We‘ve come a long way from the days of nurses manually collecting four to six sets of patient vital signs a day to the automated capture of thousands of multi-parameter measurements each day. We are not only improving the patient experience with fewer interruptions of sleep to help facilitate their healing, but we’re also giving time back to our workforce, optimizing care workflows and empowering our care team with actionable clinical insights that increase response time and improve overall patient care.”

Houston Methodist is also expanding use of the BioButton solution to help triage patients with medical-grade monitoring in the emergency department while working in parallel to operationalize a hospital to home program.

Ardent Health Services and BioIntelliSense, today announced the launch of a new continuous patient monitoring initiative to empower clinicians with greater data-driven insights for patient care and to optimize clinical and operational workflow.

Clinicians at Ardent’s BSA Hospital in Amarillo, Texas, began using the BioButton® wearable device and BioCloud™ analytics engine in September to automate the collection of inpatient vital signs in general care units and increase both patient and clinician satisfaction. With plans for expansion across Ardent’s 30 hospitals, the program also leverages BioIntelliSense’s FDA-cleared AlertWatch®, clinical intelligence and triage solution. The integrated dashboard and highly intuitive display provides clinicians a centralized view of high-frequency patient trending data and algorithmic-based alerting that supports earlier intervention.

As part of the new inpatient continuous monitoring initiative, patients wear the BioButton throughout the duration of their stay. The patient friendly device captures and wirelessly transmits up to 1,440 sets of vital sign measurements per day at a fraction of the cost of traditional, manually collected vital sign measurements, which are typically only collected 4-6 times per day. This enables clinicians to identify stable patients that may be candidates for early discharge, potentially reducing hospital stays while providing medical grade monitoring in the convenience and comfort of a patient’s home.

“This partnership is another step forward in our efforts to leverage game-changing clinical technology to transform the care delivered in and outside of our hospitals and clinics,” said Ardent Chief Executive Officer Marty Bonick. “These tools empower our clinical teams to work at the top of their license while providing actionable insights that allow us to tailor care in near real time, supporting better outcomes and an improved experience for both patients and caregivers.”

BioIntelliSense’s medical-grade BioButton® wearable device, along with its algorithmic-based data services, enable effortless remote data capture and continuous multi-parameter monitoring on a single device in both acute and post-acute settings.

“We are at a critical inflection point for healthcare where the technology now exists to enable a more intelligent model of care delivery that allows providers to take better care of more patients at a fraction of the cost,” said James Mault, MD, founder and CEO of BioIntelliSense. “We are proud to work with the committed, forward-thinking team at Ardent¹ to deliver this next standard of continuous patient monitoring, so patients get the best care when and where they need it most and hospitals get the tools they need to enable more efficient clinical workflow given the growing workforce shortage crisis.”

In combination with BioIntelliSense’s advanced BioCloud™ data analytics, patient-specific trending and clinical intelligence may allow for early detection of adverse trends and proactive interventions. The BioIntelliSense and AlertWatch solutions are integrated with Ardent’s Epic electronic health record to streamline clinical workflow and enable a high-resolution view of a patient’s health status from in-hospital to home.

BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced its acquisition of AlertWatch®, an FDA-cleared, clinically proven patient monitoring solution. AlertWatch uniquely provides robust integration, data analysis and a patented intuitive display of contextual patient data for more efficient, actionable clinical decisions. As part of the recently announced strategic partnership with Medtronic, its Patient Monitoring business will distribute AlertWatch to hospitals throughout the U.S. as a new offering in its HealthCast™ portfolio.

“The addition of AlertWatch offers healthcare providers comprehensive continuous monitoring solutions, and an accelerated path from adoption to full scale utilization,” said James Mault, MD, founder and CEO of BioIntelliSense. “The patented AlertWatch multi-parameter interface displays and analyzes data from inpatient vitals, the electronic medical record (EMR), laboratory systems and BioIntelliSense medical-grade wearables, to provide clinical intelligence across care settings and acuity levels.”

Hospitals nationwide are seeking enterprise-grade platforms that optimize labor intensive processes through automation of data capture, combined with scalable exception management and clinical insights, from in-hospital to home. Over the past decade, AlertWatch has earned 4 FDA 510(k) clearances for its specialized product offerings for the operating room, intensive care unit, and labor and delivery unit. AlertWatch is also monitoring patients in general care wards – and now, in the home.

The AlertWatch centralized triage dashboard aggregates data and provides clinicians with a composite view of patient vital sign trends, while simultaneously performing advanced analytics and alerting, for proactive clinical decisions. The AlertWatch system has been used to assist over 1 million surgeries and over 25,000 births. The AlertWatch operating room solution, when comparing users versus non-users, was associated with a 1-day reduction in post-operative length of stay (LOS) and a $3,603 reduction in encounter charges.¹

“By joining forces with BioIntelliSense, we are thrilled to greatly expand the reach and adoption of our world-class clinical decision support solution,” said Professor Kevin Tremper, MD, PhD, founder and President of AlertWatch. “The workflow automation benefits not only help to reduce hospital stays and costs, but also assist clinicians and nurses by alerting them with highly actionable information that prioritizes and personalizes patient care.”

The BioIntelliSense and AlertWatch platforms are interoperable solutions with extensive third party and EMR system integration and data exchange capabilities. BioIntelliSense remains committed to an ecosystem approach that provides the flexibility, security and scalability that is needed to support our customers’ patient monitoring needs.

”I am excited to see our partnership with BioIntelliSense expand so, together, we can help more patients in more places,” said Frank Chan, president of the Patient Monitoring business, which is part of the Medical Surgical Portfolio at Medtronic. “The addition of the AlertWatch system to our HealthCast™ portfolio of connectivity and remote monitoring solutions strengthens our commitment to patient safety and enables workflow efficiency for our customers as they monitor patients in-hospital and at-home.”

REFERENCE 1. Kheterpal S, Shanks A, Tremper KK. Impact of a novel multiparameter decision support system on intraoperative processes of care and postoperative outcomes. Anesthesiology. 2018;128(2):272-282.

Houston-based Houston Methodist and BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced a new collaboration to advance cutting-edge remote monitoring and analytics technologies across the healthcare continuum, from in-hospital to at-home. The recently executed Memorandum of Understanding (MOU) identifies several areas of strategic focus for improving patient care, increasing clinical workflow efficiencies, and reducing the burden on healthcare systems.

BioIntelliSense’s FDA-cleared BioSticker™ and medical grade BioButton® wearable devices, along with its algorithmic-based data services, enable effortless remote data capture and continuous multi-parameter monitoring of 20+ biometrics for up to 30 days on a single device. These patient-friendly wearables capture and wirelessly transmit up to 1,440 sets of vital sign measurements per day at a fraction of the cost of traditional, manually-collected vital sign measurements 4-6 times per day. In combination with BioIntelliSense’s advanced BioCloud™ data analytics, patient-specific trending and clinical intelligence allow for early detection of adverse trends and proactive interventions.

“This new strategic collaboration with BioIntelliSense exemplifies Houston Methodist’s continued commitment to advancing world-class expertise and greater efficiency to deliver the highest quality and most impactful care,” said Dr. Sarah Pletcher, Vice President and Executive Medical Director, Strategic Innovation, Houston Methodist. “This collaboration keeps the patient at the center as we continue to maximize our leadership in healthcare innovation.”

The collaboration will also address the rising costs and burdens of the growing healthcare workforce shortage. BioIntelliSense and Houston Methodist will jointly design and develop a state-of-the-art virtual care control center at Houston Methodist to enable seamless, scalable, continuous monitoring of patients across in-hospital to home care settings.

“Data-driven remote patient monitoring that is simple, clinically accurate, and cost-effective, is the future of healthcare delivery,” said James Mault, MD, Founder and CEO of BioIntelliSense. “We are proud to work alongside our partners at Houston Methodist to pioneer a continuous care model that provides actionable data and clinical intelligence to enable our overburdened healthcare workforce take better care of patients in any care setting.”

The MOU further establishes the use of leading biosensor technology and the development of advanced algorithms, care models, and data analytics for monitoring and treating a range of complex conditions spanning heart and vascular, orthopedics, oncology, infectious diseases, transplants, and others.

BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, expands its commitment to creating a new standard of remote patient care with the commercial launch of its medical grade BioButton® Rechargeable wearable device. The new BioButton Rechargeable device allows for continuous multi-parameter monitoring of a broad range of 20+ vital signs and physiologic biometrics for up to 30 days on a single charge. The device’s comprehensive set of leading indicators allows for the early identification and detection of adverse trends to improve patient monitoring safety and efficacy from in the hospital to the home. This newest addition to BioIntelliSense’s leading portfolio of medical grade wearable devices and data services provides a simplified and cost-effective continuous monitoring solution for managing patient populations with chronic, complex care needs month-over-month or for even years.

The introduction of the BioButton Rechargeable device reduces the labor intensive and costly burden of intermittent in-person collection of routine vital signs by health professionals and enables continuous proactive remote care. Along with the flagship FDA-cleared BioSticker™ medical device, the BioButton Rechargeable provides continuous multi-parameter monitoring with up to 1,440 passive vital sign measurements per day, versus episodic manual vital sign collection at the patient bedside 4-6 times per day. The high-fidelity data capture offers the opportunity to identify adverse trends earlier in their course and helps address the mounting healthcare workforce shortage through automation of routine vital signs collection.

“Our commitment to making remote patient care ubiquitous and scalable is further advanced with the introduction of the BioButton Rechargeable device, and accelerates remote monitoring initiatives within the hospitals, provider organizations and payors that are seeking medical-grade continuous monitoring solutions that combine an effortless user experience with clinical accuracy,” said James Mault, MD, Founder and CEO of BioIntelliSense. “The BioButton Rechargeable is the easy button for a healthcare workforce in crisis, realizing a new standard in remote care that is effortless for the patient and clinician, while allowing providers to scale care without scaling costs.”

The BioButton Rechargeable device offers a comprehensive range of 20+ patient trending and algorithmic-based personalized alerts including temperature, resting heart rate, respiratory rate, body position, activity levels, gait analysis, infection-like symptoms and more. The BioIntelliSense continuous monitoring solutions are being rapidly adopted and deployed in the U.S. and select international markets for medical-grade monitoring across care settings namely in-patient status monitoring, hospital at home, ED observation, post-discharge complex care management and remote monitoring at home. Learn more about how BioIntelliSense is making early detection simple™ at the HIMSS Global Health Conference & Exhibition March 14-18, 2022 in Orlando, Florida.